Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alkermes plc.ALKS · Entity 2392 | EVP R&D, Chief Medical Officer | September 01, 2026 | September 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alkermes plc.
Report date September 01, 2026 · Filed September 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 65,389 |
Ending reported balance
After 2026-09-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-01 · Exercise / conversion · Acquired 5,000 · Balance 74,389 F1: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. Row 2 · 2026-09-01 · Sale · Disposed 9,000 · Balance 65,389 F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.8269 to $47.3197. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.59 · Expires 2032-02-18 | Direct | 61,276 |
Reported balance
After 2026-09-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-01 · Exercise / conversion · Disposed 5,000 · Balance 61,276 F1: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F4: These options are fully vested in accordance with their terms. |
Filing footnotes · ownership attribution and instrument terms
F1: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.8269 to $47.3197. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.
F4: These options are fully vested in accordance with their terms.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALBIREO PHARMA, INC.
Report date March 02, 2023 · Filed March 02, 2023
Section 16 reporting ended · disclosed 2023-03-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-02 · Disposition to issuer · Disposed 10,495 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer, $0.01 par value per share (each, a "Share"). F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the "Merger Agreement"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation ("Parent"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee ("Guarantor"), and the Issuer, pursuant to which Purchaser completed a tender offer for Share and thereafter merged with and into the Issuer (the "Merger"), effective as of March 2, 2023 (the "Effective Time"). F3: (Continued from Footnote 2) At the Effective Time, (a) each outstanding restricted stock unit (each, a "Company RSU") that was granted prior to the date of the Merger Agreement, and each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as an "Accelerated 2023 RSU," was canceled and converted into the right to receive (1) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time multiplied by (y) $42.00 and (2) one non-tradeable contractual contingent value right ("CVR") for each Share subject to such Company RSU immediately prior to the Effective Time, which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement on or prior to December 31, 2027; F4: (Continued from Footnote 3) and (b) each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as a "Cancelled 2023 RSU" was canceled and had no further force or effect. F5: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer, $0.01 par value per share (each, a "Share").
F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the "Merger Agreement"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation ("Parent"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee ("Guarantor"), and the Issuer, pursuant to which Purchaser completed a tender offer for Share and thereafter merged with and into the Issuer (the "Merger"), effective as of March 2, 2023 (the "Effective Time").
F3: (Continued from Footnote 2) At the Effective Time, (a) each outstanding restricted stock unit (each, a "Company RSU") that was granted prior to the date of the Merger Agreement, and each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as an "Accelerated 2023 RSU," was canceled and converted into the right to receive (1) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time multiplied by (y) $42.00 and (2) one non-tradeable contractual contingent value right ("CVR") for each Share subject to such Company RSU immediately prior to the Effective Time, which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement on or prior to December 31, 2027;
F4: (Continued from Footnote 3) and (b) each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as a "Cancelled 2023 RSU" was canceled and had no further force or effect.
F5: Not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 03, 2025 Filed Dec 5, 2025 21:21 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 3,748 | $19.34 | $72,486.32 |
DisclosureSEC source: 0001520262-25-000014 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,488 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. Read SEC document |
| December 01, 2025 Filed Dec 1, 2025 22:41 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 4,000 | $29.30 | $117,200.00 |
DisclosureSEC source: 0001520262-25-000012 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,740 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. Read SEC document |
| November 03, 2025 Filed Nov 3, 2025 21:37 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $19.34 | $0.00 |
DisclosureSEC source: 0001520262-25-000010 · form4.xml · derivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,104 Underlying: Ordinary Shares · 5,000 shares Expires 2031-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F4 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| November 03, 2025 Filed Nov 3, 2025 21:37 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 9,000 | $30.38 | $273,441.60 |
DisclosureSEC source: 0001520262-25-000010 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,740 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.34 to $30.56. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| November 03, 2025 Filed Nov 3, 2025 21:37 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 5,000 | $19.34 | $96,700.00 |
DisclosureSEC source: 0001520262-25-000010 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. Read SEC document |
| October 15, 2025 Filed Oct 15, 2025 22:47 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $19.34 | $0.00 |
DisclosureSEC source: 0001520262-25-000008 · form4.xml · derivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,104 Underlying: Ordinary Shares · 5,000 shares Expires 2031-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F4 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| October 15, 2025 Filed Oct 15, 2025 22:47 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 9,000 | $31.53 | $283,776.30 |
DisclosureSEC source: 0001520262-25-000008 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,740 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F3 · shares: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.51 to $31.60. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| October 15, 2025 Filed Oct 15, 2025 22:47 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 5,000 | $19.34 | $96,700.00 |
DisclosureSEC source: 0001520262-25-000008 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 22:16 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 6,866 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-007313 · form4.xml · derivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,598 Underlying: Ordinary Shares · 6,866 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/26/2025. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/26/2025. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 22:16 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 3,049 | $34.80 | $106,089.96 |
DisclosureSEC source: 0001127602-25-007313 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,740 Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 22:16 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 6,866 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-007313 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 23, 2025 Filed Feb 25, 2025 23:35 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 7,689 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-006718 · form4.xml · derivative · entry 6 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,379 Underlying: Ordinary Shares · 7,689 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024. Read SEC document |
| February 23, 2025 Filed Feb 25, 2025 23:35 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 3,414 | $35.32 | $120,582.48 |
DisclosureSEC source: 0001127602-25-006718 · form4.xml · nonDerivative · entry 4 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,923 Read SEC document |
| February 23, 2025 Filed Feb 25, 2025 23:35 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 7,689 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-006718 · form4.xml · nonDerivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,337 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 22, 2025 Filed Feb 25, 2025 23:35 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 12,279 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-006718 · form4.xml · derivative · entry 5 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 12,279 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| February 22, 2025 Filed Feb 25, 2025 23:35 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 5,452 | $35.32 | $192,564.64 |
DisclosureSEC source: 0001127602-25-006718 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,648 Read SEC document |
| February 22, 2025 Filed Feb 25, 2025 23:35 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 12,279 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-006718 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 19, 2025 Filed Feb 20, 2025 22:13 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 30,692 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-006033 · form4.xml · derivative · entry 5 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,692 Underlying: Ordinary Shares · 30,692 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F4 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/19/2026. F4 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/19/2026. Read SEC document |
| February 19, 2025 Filed Feb 20, 2025 22:13 UTC | Alkermes plc. ALKS · Entity 2392 | GrantEmployee Stock Option (Right to Buy) · Derivative | 63,991 | $0.00 Strike: $35.84 | $0.00 |
DisclosureSEC source: 0001127602-25-006033 · form4.xml · derivative · entry 4 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,991 Underlying: Ordinary Shares · 63,991 shares Expires 2035-02-19 F3 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/19/2026. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:13 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 8,896 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-006033 · form4.xml · derivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,897 Underlying: Ordinary Shares · 8,896 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:13 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 3,950 | $35.90 | $141,805.00 |
DisclosureSEC source: 0001127602-25-006033 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,821 Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:13 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 8,896 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-006033 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,771 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 22:12 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 35,586 | $0.00 Strike: $24.59 | $0.00 |
DisclosureSEC source: 0001127602-25-004948 · form4.xml · derivative · entry 12 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,172 Underlying: Ordinary Shares · 35,586 shares Expires 2032-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. F9 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/18/2023. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 22:12 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 108,833 | $0.00 Strike: $31.93 | $0.00 |
DisclosureSEC source: 0001127602-25-004948 · form4.xml · derivative · entry 11 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 108,833 shares Expires 2029-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. F7 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 22:12 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 108,833 | $36.02 | $3,920,001.41 |
DisclosureSEC source: 0001127602-25-004948 · form4.xml · nonDerivative · entry 8 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,875 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.00 to $36.05. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 22:12 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 35,586 | $34.02 | $1,210,696.22 |
DisclosureSEC source: 0001127602-25-004948 · form4.xml · nonDerivative · entry 7 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 166,708 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.00 to $34.07. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 22:12 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 35,586 | $24.59 | $875,059.74 |
DisclosureSEC source: 0001127602-25-004948 · form4.xml · nonDerivative · entry 6 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 202,294 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 22:12 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 108,833 | $31.93 | $3,475,037.69 |
DisclosureSEC source: 0001127602-25-004948 · form4.xml · nonDerivative · entry 5 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 166,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:12 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 111,630 | $0.00 Strike: $19.34 | $0.00 |
DisclosureSEC source: 0001127602-25-004948 · form4.xml · derivative · entry 10 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,104 Underlying: Ordinary Shares · 111,630 shares Expires 2031-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. F8 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/22/2022. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:12 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 87,566 | $0.00 Strike: $20.03 | $0.00 |
DisclosureSEC source: 0001127602-25-004948 · form4.xml · derivative · entry 9 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 87,566 shares Expires 2030-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. F7 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:12 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 33,108 | $33.27 | $1,101,470.05 |
DisclosureSEC source: 0001127602-25-004948 · form4.xml · nonDerivative · entry 4 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,875 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.00 to $33.52. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:12 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 171,813 | $32.69 | $5,616,807.51 |
DisclosureSEC source: 0001127602-25-004948 · form4.xml · nonDerivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,983 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.00 to $32.9998. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:12 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 111,630 | $19.34 | $2,158,924.20 |
DisclosureSEC source: 0001127602-25-004948 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 262,796 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:12 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 87,566 | $20.03 | $1,753,946.98 |
DisclosureSEC source: 0001127602-25-004948 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. Read SEC document |
| February 06, 2025 Filed Feb 8, 2025 01:31 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 15,083 | $31.39 | $473,455.37 |
DisclosureSEC source: 0001127602-25-003679 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,600 Read SEC document |
| February 06, 2025 Filed Feb 8, 2025 01:31 UTC | Alkermes plc. ALKS · Entity 2392 | GrantOrdinary Shares | 34,393 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-003679 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,683 F1 · price: These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 18, 2022 with a three-year performance period that ended on December 31, 2024 (the "2022 PRSUs"). The vesting of this portion of the 2022 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a total shareholder return modifier and represents the final vesting event under the 2022 PRSUs. Read SEC document |
| January 30, 2025 Filed Feb 1, 2025 01:42 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 18,345 | $0.00 Strike: $26.82 | $0.00 |
DisclosureSEC source: 0001127602-25-002645 · form4.xml · derivative · entry 9 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,271 Underlying: Ordinary Shares · 18,345 shares Expires 2033-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. F7 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024. Read SEC document |
| January 30, 2025 Filed Feb 1, 2025 01:42 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 23,542 | $0.00 Strike: $24.59 | $0.00 |
DisclosureSEC source: 0001127602-25-002645 · form4.xml · derivative · entry 8 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,758 Underlying: Ordinary Shares · 23,542 shares Expires 2032-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. F6 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/18/2023. Read SEC document |
| January 30, 2025 Filed Feb 1, 2025 01:42 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 26,589 | $0.00 Strike: $19.34 | $0.00 |
DisclosureSEC source: 0001127602-25-002645 · form4.xml · derivative · entry 7 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 161,734 Underlying: Ordinary Shares · 26,589 shares Expires 2031-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. F5 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/22/2022. Read SEC document |
| January 30, 2025 Filed Feb 1, 2025 01:42 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 29,156 | $0.00 Strike: $20.03 | $0.00 |
DisclosureSEC source: 0001127602-25-002645 · form4.xml · derivative · entry 6 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,566 Underlying: Ordinary Shares · 29,156 shares Expires 2030-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. F4 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| January 30, 2025 Filed Feb 1, 2025 01:42 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 100,918 | $32.05 | $3,234,381.53 |
DisclosureSEC source: 0001127602-25-002645 · form4.xml · nonDerivative · entry 5 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,290 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.00 to $32.17. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| January 30, 2025 Filed Feb 1, 2025 01:42 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 18,345 | $26.82 | $492,012.90 |
DisclosureSEC source: 0001127602-25-002645 · form4.xml · nonDerivative · entry 4 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,208 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. Read SEC document |
| January 30, 2025 Filed Feb 1, 2025 01:42 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 23,542 | $24.59 | $578,897.78 |
DisclosureSEC source: 0001127602-25-002645 · form4.xml · nonDerivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. Read SEC document |
| January 30, 2025 Filed Feb 1, 2025 01:42 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 26,589 | $19.34 | $514,231.26 |
DisclosureSEC source: 0001127602-25-002645 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,321 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. Read SEC document |
| January 30, 2025 Filed Feb 1, 2025 01:42 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 29,156 | $20.03 | $583,994.68 |
DisclosureSEC source: 0001127602-25-002645 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 01:53 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 12,411 | $0.00 Strike: $26.82 | $0.00 |
DisclosureSEC source: 0001127602-24-028885 · form4.xml · derivative · entry 9 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,616 Underlying: Ordinary Shares · 12,411 shares Expires 2033-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. F7 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 01:53 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 12,044 | $0.00 Strike: $24.59 | $0.00 |
DisclosureSEC source: 0001127602-24-028885 · form4.xml · derivative · entry 8 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,300 Underlying: Ordinary Shares · 12,044 shares Expires 2032-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. F6 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/18/2023. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 01:53 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 12,090 | $0.00 Strike: $19.34 | $0.00 |
DisclosureSEC source: 0001127602-24-028885 · form4.xml · derivative · entry 7 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 188,323 Underlying: Ordinary Shares · 12,090 shares Expires 2031-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. F5 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/22/2022. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 01:53 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 12,452 | $0.00 Strike: $20.03 | $0.00 |
DisclosureSEC source: 0001127602-24-028885 · form4.xml · derivative · entry 6 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,722 Underlying: Ordinary Shares · 12,452 shares Expires 2030-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. F4 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 01:53 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 61,151 | $32.07 | $1,961,406.09 |
DisclosureSEC source: 0001127602-24-028885 · form4.xml · nonDerivative · entry 5 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,576 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.00 to $32.2514. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.